Quoin Pharmaceuticals (QNRX)
NASDAQ:QNRX
Want to see QNRX full AI Analyst Report?
Top Page
Quoin Pharmaceuticals
(NASDAQ:QNRX)
Select Model
Select Model
Rating:47Neutral
Price Target:
$5.50
▼(-53.07% Downside)
Action:ReiteratedDate:03/27/26
The score is held down primarily by weak financial performance (no revenue, ongoing losses, and elevated cash burn, with deterioration in the latest period) and a bearish technical trend. Offsetting these risks are constructive corporate events around QRX003 regulatory acceleration, while valuation signals are not informative given the provided P/E and missing dividend yield.
Positive Factors
Regulatory Acceleration
Fast Track status gives QRX003 more FDA interactions, eligibility for rolling review and accelerated pathways. This structurally shortens development/review timelines and raises the probability of earlier approval and commercial access for a first-in-class rare disease therapy.
Negative Factors
Pre-revenue & Persistent Losses
Zero revenue and recurring multi-year net losses mean the company must fund operations externally until commercialization. This creates lasting dilution and financing risk that can pressure strategy execution and extend timelines for sustainable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory Acceleration
Fast Track status gives QRX003 more FDA interactions, eligibility for rolling review and accelerated pathways. This structurally shortens development/review timelines and raises the probability of earlier approval and commercial access for a first-in-class rare disease therapy.
Read all positive factors
Quoin Pharmaceuticals (QNRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.72M
Dividend YieldN/A
Average Volume (3M)629.04K
Price to Earnings (P/E)―
Beta (1Y)-1.13
Revenue GrowthN/A
EPS Growth-228.89%
CountryUS
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.74
Shares Outstanding1,803,626
10 Day Avg. Volume1,633,105
30 Day Avg. Volume629,040
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.17
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-392.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit151.63K
Enterprise Value/Ebitda233.73
Forecast
1Y Price Target
$37.50Price Target Upside219.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.38
Revenue Forecast (FY)N/A
Quoin Pharmaceuticals Business Overview & Revenue Model
Company Description
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops ...
How the Company Makes Money
null...
Quoin Pharmaceuticals Earnings Call Summary
Earnings Call Date:Mar 13, 2024
(Q4-2023)
| % Change Since: |
Next Earnings Date:May 13, 2026
Earnings Call Sentiment Positive
The earnings call reflects a generally positive outlook for Quoin Pharmaceuticals, with significant progress in clinical trials, strong commercial partnerships, and a solid financial position. However, challenges remain in managing cash burn and executing M&A strategies.Positive Updates
Transformational Year for Quoin
2023 was a transformational year for Quoin, marked by the release of the first-ever clinical data from a trial in Netherton syndrome subjects under an open IND with the FDA. The initial data was positive across several clinical endpoints with no safety signals.
Negative Updates
Net Loss and Cash Burn
Despite a decrease in net loss from $9.4 million in 2022 to $8.7 million in 2023, Quoin still faces financial challenges with ongoing R&D expenses and a net loss of $2 million in Q4 2023.
Read all updates
Q4-2023 Updates
Positive
Negative
Transformational Year for Quoin
2023 was a transformational year for Quoin, marked by the release of the first-ever clinical data from a trial in Netherton syndrome subjects under an open IND with the FDA. The initial data was positive across several clinical endpoints with no safety signals.
Read all positive updates
Company Guidance
During the Q4 2023 earnings call for Quoin Pharmaceuticals (QNRX), key guidance included updates on clinical trials for QRX003, a potential treatment for Netherton syndrome. The company implemented several FDA-cleared protocol amendments, including increasing study size, altering dosing frequency, and lowering eligibility age to 14 years. They have 9 commercial partnerships covering 61 countries and completed a $6.5 million public offering, with an $8 million equity line of credit to extend their cash runway into the second half of 2026. Despite a net loss of $8.7 million for 2023, Quoin remains the only company with an open IND for Netherton syndrome, positioning itself for a pivotal year in 2024.Quoin Pharmaceuticals Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
58
Neutral
Cash Flow
14
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -100.79K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -16.32M | -9.43M | -9.27M | -8.56M | -20.27M |
| Net Income | -15.80B | -8.96M | -8.69M | -9.38M | -21.46M |
Balance Sheet | |||||
| Total Assets | 20.39M | 15.71M | 12.17M | 14.46M | 9.36M |
| Cash, Cash Equivalents and Short-Term Investments | 3.82B | 14.06M | 10.69M | 12.85M | 7.48M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 7.27M | 6.50M | 6.51M | 7.05M | 8.70M |
| Stockholders Equity | 13.12M | 9.20M | 5.66M | 7.41M | 657.03K |
Cash Flow | |||||
| Free Cash Flow | -13.54B | -7.86M | -7.86M | -8.73M | -6.35M |
| Operating Cash Flow | -13.54B | -7.86M | -7.86M | -8.48M | -5.72M |
| Investing Cash Flow | -4.28B | -1.89M | 2.19M | -10.15M | -625.00K |
| Financing Cash Flow | 18.01B | 10.97M | 5.22M | 14.01M | 13.50M |
Quoin Pharmaceuticals Technical Analysis
Negative
11.72
Price Trends
7.71
Negative
10.41
Negative
9.94
Negative
Market Momentum
-0.50
Negative
43.91
Neutral
67.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QNRX, the sentiment is Negative. The current price of 11.72 is above the 20-day moving average (MA) of 6.77, above the 50-day MA of 7.71, and above the 200-day MA of 9.94, indicating a bearish trend. The MACD of -0.50 indicates Negative momentum. The RSI at 43.91 is Neutral, neither overbought nor oversold. The STOCH value of 67.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QNRX.
Quoin Pharmaceuticals Risk Analysis
Quoin Pharmaceuticals disclosed 57 risk factors in its most recent earnings report. Quoin Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Quoin Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $9.72M | ― | -334.42% | ― | ― | -228.89% | |
45 Neutral | $5.58M | ― | 9999.00% | ― | 12.45% | -544.23% | |
44 Neutral | $2.31M | -0.46 | -155.01% | ― | ― | 78.52% | |
43 Neutral | $4.63M | -0.31 | -46.34% | ― | ― | 70.71% | |
40 Underperform | $2.95M | -0.52 | ― | ― | ― | 87.42% |
* Healthcare Sector Average
QNRX
Quoin Pharmaceuticals
6.46
0.79
13.93%
GLMD
Galmed Pharmaceuticals
0.76
-0.64
-46.07%
JAGX
Jaguar Animal Health
0.40
-5.23
-92.97%
ADIL
Adial Pharmaceuticals
1.63
-14.62
-89.97%
ALZN
Alzamend Neuro
1.12
-4.99
-81.68%
CLDI
Calidi Biotherapeutics
0.28
-5.01
-94.79%
Quoin Pharmaceuticals Corporate Events
Business Operations and StrategyProduct-Related Announcements
Quoin Wins FDA Fast Track for QRX003 in Netherton
Positive
Mar 12, 2026
On March 11, 2026, Quoin Pharmaceuticals announced that the U.S. Food and Drug Administration granted Fast Track Designation to QRX003 lotion (4%) for the treatment of Netherton Syndrome, a rare, inherited skin disorder with no approved therapies....
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Quoin seeks Saudi breakthrough status for Netherton therapy
Positive
Jan 20, 2026
On January 20, 2026, Quoin Pharmaceuticals announced that it had filed an application with the Saudi Food and Drug Authority for Breakthrough Medicine Designation for QRX003, its lead late-stage topical candidate for Netherton Syndrome, a rare and...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.